Remove 2029 Remove Drug Development Remove Marketing Remove Pharmaceuticals
article thumbnail

Thirteen potential blockbuster drugs to watch in 2024

Drug Discovery World

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 173
article thumbnail

Inside the Altascientist: Considerations for Safe and Compliant HPAPI Manufacturing

Alta Sciences

Inside the Altascientist: Considerations for Safe and Compliant HPAPI Manufacturing pmjackson Fri, 03/08/2024 - 19:35 In recent years, advancements in oncological research have fueled a surge in demand for highly potent active pharmaceutical ingredients ( HPAPIs ). So much so that the HPAPI market is estimated to reach USD 31.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What is the largest CRO in the US?

Vial

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). By geographical region, the global CRO services market in 2023 was dominated by North America. As a result, the global CRO market is estimated to grow at a compound annual growth rate (CAGR) of 9.6%

article thumbnail

Fewer New Drugs but Affordable Access for Existing Ones: The Big Elephant in the Room

Policy Prescription

Would you vote for legislation to lower drug prices that would lead to a five percent reduction in pharmaceutical innovation — yet simultaneously create a health system in which all Americans could afford the prescription drugs they need? 3 contained policies to negotiate drug prices for Medicare. I would vote for it.

Drugs 52
article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

This means that the medical device frameworks – including the pre-market pathways and evidentiary requirements, as well as post-market quality system frameworks and reporting requirements – are applied to the vast majority of all (CDRH-regulated) IVD products. IVDs used in blood donation screening/processing). In the E.U.,

FDA 40